In plain terms

The claim being assessed: Research-chemical-sourced GLP-1 analogues deliver the efficacy demonstrated in registrational trials.

Where the evidence stands: Α — Speculative. An idea with a story behind it, but no evidence yet that it actually happens.

What this mechanism does: The evidence reviewed does not show this mechanism causing the outcome. That does not show it has no effect.

Strongest evidence for it: Overall Α applies to SC3, the preregistered clinical-equivalence proposition. It does not deny the efficacy of regulated GLP-1 medicines or prove that every research-market preparation is inactive. Product identity, exposure and clinical equivalence cannot be supplied by a chemical label or transferred from a registrational trial.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

Regulated GLP-1 medicines have causal clinical evidence; equivalent efficacy of unregulated research-chemical products has not been established.

Implications for health and treatment: Overall Α applies to SC3, the preregistered clinical-equivalence proposition. It does not deny the efficacy of regulated GLP-1 medicines or prove that every research-market preparation is inactive. Product identity, exposure and clinical equivalence cannot be supplied by a chemical label or transferred from a registrational trial.

Limits for individual care: 51 primary reports with 1 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Figures

Explanatory figures summarizing this review. They carry no evidential weight of their own; where a figure and the review differ, the review governs.

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 51 primary reports; claims: 55; verified: 55; unverified: 0. Verification is bounded attribution. Access: 1 partial-body and 50 bounded abstract/status examinations. Literature cutoff: 2026-10-09; source examination UTC date: 2026-10-10. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 5 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Regulated GLP-1 medicines have causal clinical evidence; equivalent efficacy of unregulated research-chemical products has not been established.

Deciding experiment: Compare independently assayed candidate preparations against the authentic trial product under ethically authorized product-quality and clinical-trial oversight, with prespecified exposure and clinical equivalence margins; assay every batch before outcomes.

Belief versus evidence: Overall Α applies to SC3, the preregistered clinical-equivalence proposition. It does not deny the efficacy of regulated GLP-1 medicines or prove that every research-market preparation is inactive. Product identity, exposure and clinical equivalence cannot be supplied by a chemical label or transferred from a registrational trial.

Best-supported rival: Authentic-product pharmacology with exposure-dependent effects. An independently assayed, formulation- and exposure-controlled clinical comparison would separate authentic equivalent exposure from variable supply. Existing registrational trials do not provide that comparison.

COMPETING MECHANISTIC MODELS

Rank 1: Authentic-product pharmacology with exposure-dependent effects (Ε). Known formulation and verified delivery determine the tested therapeutic effect. Randomized weight and clinical-outcome trials support authentic formulations. This does not guarantee every supplier, batch, dose or clinical population.

Rank 2: Variable identity, formulation and administration (Β). Supply and administration variation can change exposure independently of the advertised target. Direct online-product assays and a counterfeit case demonstrate possible mismatches. Small selected samples and reporting systems cannot quantify the whole market.

Rank 3: Research-market clinical equivalence (Α). The advertised peptide label is treated as sufficient to transfer trial efficacy. Some purchased samples contained semaglutide and licensed products work. Presence does not establish purity, potency, exposure, sterility or clinical equivalence.

Rank 4: Expectation, co-use and selection (Β). Self-reported outcomes may reflect other interventions or selective reporting. Qualitative use reports document co-use and unverified sourcing. No adequate comparator quantifies this contribution.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Research-chemical-sourced GLP-1 analogues deliver the efficacy demonstrated in registrational trials.

The website claim hinges on SC3 at its stated scope; SC1 and SC2 are reported separately and cannot substitute for that claim.

Selection: remaining-priority list position 1 from the editorial list of 2026-10-09. No prior grade consulted; this is not independent blinded calibration.

Evidence and causal interpretation

Rubric fit: 06-metabolism-aging is the closest metabolic rubric, but its organismal-aging language is a poor fit to supply-chain equivalence. The universal ladder and causal-scope rules govern the nominal product claim. SC1 includes randomized clinical/functional outcomes, not weight biomarkers alone. SC2 and SC3 do not inherit aging-specific thresholds. The initially listed psychiatry secondary rubric was removed before adjudication as irrelevant; the original preregistration is retained unchanged.

The strongest evidence is for authentic interventions. STEP and SURMOUNT trials causally change weight, and FLOW/SELECT and selected functional studies extend support to clinical outcomes. These successes are scored separately: the tested exposure includes the molecule, formulation, manufacture and delivery. Different GLP-1, dual GIP/GLP-1 and triple-target agents are not chemically interchangeable. [9] [13] [30] [5] [8]

Direct product testing addresses a different question. The online-purchase study found the named peptide alongside label/analytical mismatches in only a few delivered samples. The Results body qualifies two endotoxin measurements as upper bounds; this review therefore does not repeat a range as if all were measured positive concentrations. Analytical impurity findings likewise do not identify the clinical toxicity of every contaminant. [1] [46]

Compounded products, falsified branded products and research chemicals are different categories. Poison reports, adverse-event surveillance and a falsified-product case identify credible failure possibilities, but lack a representative exposed-user denominator. They neither measure market-wide harm nor establish trial-equivalent benefit. [2] [49] [50] [51]

The decisive gap is controlled clinical equivalence under verified exposure. Uncontrolled body-composition changes or interviews cannot supply this missing bridge. The assessment is Α for the supply-to-clinical-equivalence claim, with stronger authentic-product evidence preserved rather than downgraded. [47] [48]

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Consensus consistency validation — 9 October 2026

Cutoff: 2026-10-09. Provider artifact: consensus-browser-response.md (verbatim, citation markers preserved), browser-thread.json, and consensus-search-raw.json. Consensus thread: Grey Market Semaglutide Quality, Pro. The provider’s broad summary is directionally consistent with the narrow preregistered claim, but some wording (“frequently”, “fails … safety”) overgeneralizes from small product samples and pharmacovigilance reports; those formulations are not adopted as verified population-level facts.

Primary-source reconciliation

• PMID 39509151; DOI 10.2196/65440; Ashraf et al. 2024, JMIR. Directly procured six online purchases yielded three completed deliveries, all three of which were falsified/substandard; the paper reports peptide purity 7.7–14.37%, content 28.56–38.69% above label, and endotoxin in samples. Original package ledger source 1, study key PMID39509151, selected full-text body passages; already included. The Consensus report’s second citation carried no PMID in its own metadata; it resolves in PubMed as PMID 39093567; DOI 10.1001/jamanetworkopen.2024.28280, a related Ashraf/Mackey research letter on online test purchases and risk assessment, not independent evidence of a second random market sample. Treat it as the same research/test-purchase evidence family unless exact methods establish independent sampling; do not add an independent study count.
• PMID 41125326; DOI 10.1136/ejhpharm-2025-004656; Antonacci et al. 2025. Primary case report documents a 31-year-old patient in hypoglycemic coma after a website-sourced product; toxicology identified insulin rather than semaglutide. Original package ledger source 51, already included. One verified case establishes a real counterfeit hazard, not frequency or prevalence.
• PMID 42137313; DOI 10.3389/fphar.2026.1805842; Zinzi et al. 2026. Primary EudraVigilance analysis (2018–2025 reports) retrieves 234 ICSRs related to potential counterfeit semaglutide and reports disproportionality signals. PubMed primary abstract checked. Not found in the frozen 51-source ledger by PMID/DOI; supplemental only, not counted in original source total. Voluntary reports lack exposure denominators and confirmed product authentication; they support a signal, not comparative incidence or causation.
• PMID 39379664; DOI 10.1007/s11095-024-03771-6; Hach et al. 2024. Analytical testing of follow-on GLP-1 products; original evidence ledger already contains it. Its sampling and product category do not establish market-wide grey-market prevalence or clinical consequences.

Claim/score judgement

SC1 regulated trial products effective (Ε): no change; Consensus did not add a new controlled regulated-product result. SC2 unregulated research-chemical supply reliably reproduces identity/purity/concentration/sterility (Β): no change; direct product testing and one falsified-product case remain specific samples/events. SC3 unregulated products reproduce clinical efficacy of trial products (Α): no change; no direct comparative efficacy trial was identified. The new 2026 pharmacovigilance report adds a signal but does not bridge authentication, denominator, or causal exposure gaps. Original score and counts remain Α / Moderate; 51 reports, 55 verified claims. No grade/scorecard patch proposed.

This reconciliation verifies provider-discovered citations against original primary records; it is not an independent blinded review. No Consensus evidence-strength tags were used as quality tiers.

Primary record links

PMID 39509151 · PMID 41125326 · PMID 42137313 · PMID 39379664 - PMID 42533250; DOI 10.1007/s11095-026-04146-9; Kopp et al. 2026. Consensus keyword search/fetch surfaced this primary in-vitro study (raw tool record saved as consensus-fetch-76090d1d936b5dc3bd8a635ced882462.json); PubMed bibliographic record identifies publication in 2026, within cutoff. It examined follow-on/compounded GLP-1 products, distinct impurity profiles, and in-vitro peptide presentation with potential immunogenicity. This is not a directly tested grey-market online sample nor a patient immunogenicity/outcome study. Its findings are adjacent evidence only, and the authors include Novo Nordisk employees/shareholders. Not present in frozen selected-records.json; supplemental, outside original count.

This dated supplement adds source reconciliation to the original review. Its original narrative, registered scope, source inventory and grades remain historical records. No adversarial approval was attached to this case before 14 October 2026, so this supplement neither carries nor extends one. New sources described here are supplemental and are not counted in the original inventory.

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. Overall Α applies to SC3, the preregistered clinical-equivalence proposition. It does not deny the efficacy of regulated GLP-1 medicines or prove that every research-market preparation is inactive. Product identity, exposure and clinical equivalence cannot be supplied by a chemical label or transferred from a registrational trial. Sensitivities: weakest-link Α; primary-subclaim Α; scope-matched Α.

Decisive-perturbation inventory and causal tally

[5] SELECT randomized semaglutide reduced cardiovascular events in obesity with prior cardiovascular disease. This is regulated-product efficacy in a selected high-risk population, not identity or bioequivalence of online vials.

[6] SURMOUNT-5 randomized comparison favored tirzepatide over semaglutide for weight loss. Open-label comparison and dual receptor pharmacology do not establish equivalence of research-sourced molecules.

[7] OASIS-4 found weight reduction with the tested oral semaglutide formulation. Formulation-specific trial results cannot establish absorption or efficacy of a different product.

[8] STEP-9 improved weight, knee pain and function with semaglutide in obesity and knee osteoarthritis. Weight mediation and the selected clinical context remain; unregulated sourcing was not tested.

[9] STEP-1 demonstrated weight loss with randomized regulated semaglutide. Authentic trial-product exposure is the controlled variable; a supplier's chemical name alone is not that exposure.

[10] STEP-TEENS reduced BMI with semaglutide in adolescents. Developmental context and BMI endpoints differ from adult outcomes; no online-product comparison.

[11] STEP-5 showed sustained weight loss over two years with semaglutide. Sustained trial efficacy does not establish batch consistency elsewhere.

[12] STEP-4 continuation maintained weight loss whereas withdrawal led to regain. The randomized population completed a tolerability run-in; withdrawal of an authentic product is not a supply-chain test.

[13] SURMOUNT-1 demonstrated weight reduction with tirzepatide. Dual GIP/GLP-1 action and regulated manufacture cannot be assigned to an unassayed vial.

[14] SURMOUNT-4 continuation and withdrawal separated weight trajectories. Run-in selection restricts generality; the trial does not establish unregulated equivalence.

[15] SURMOUNT-CN found weight reduction with tirzepatide in a Chinese population. The attached erratum was identified but not fully audited; product equivalence remains untested.

[16] SURMOUNT-OSA reduced apnea severity and weight with tirzepatide. Weight-related mediation and the attached erratum limit a broad mechanism inference; no grey-market arm.

[17] Longer SURMOUNT-1 follow-up supported diabetes prevention in obesity with prediabetes. This is a later report of the same trial family, not an independent manufacturing or mechanism test.

[18] SUMMIT improved the cardiovascular-death/worsening-heart-failure composite and function in obesity with HFpEF. Composite benefit does not prove a mortality-alone effect or unregulated equivalence.

[19] SURMOUNT-3 improved weight after an intensive lifestyle lead-in. Lead-in eligibility and an attached erratum restrict interpretation; authentic formulation was tested.

[20] SURMOUNT-2 improved weight in obesity with type 2 diabetes. Diabetic context differs from other populations; sourcing equivalence was not randomized.

[24] Liraglutide after an endoscopic bariatric procedure improved weight outcomes under tested timing conditions. Procedure and timing restrict generalization; no grey-market sourcing comparison.

[25] Liraglutide supported weight loss after gastric bypass. Pandemic-related attrition and a postsurgical population limit generality.

[26] Liraglutide-induced weight loss occurred without measured changes in food liking in the tested study. A null selected mediator measure does not rule out all appetite mechanisms or test unregulated products.

[27] STEP-8 favored semaglutide over liraglutide for weight loss. Comparative authentic formulations do not establish equivalence across suppliers.

[28] SCALE supported liraglutide-induced weight loss. This supports licensed intervention efficacy, not research-market efficacy.

[29] Liraglutide reduced BMI in children under the study conditions. Childhood growth and BMI outcomes cannot be read as universal adult weight loss.

[30] FLOW reduced a clinical kidney/cardiovascular composite in type 2 diabetes with CKD. Disease scope is constrained; no unregulated preparation was assessed.

[31] SOUL reduced major cardiovascular events with oral semaglutide. Confirmatory secondary endpoints were not all positive; trial formulation is material to the result.

[32] SUSTAIN-6 supported cardiovascular noninferiority and reported more retinopathy complications. A benefit signal does not make all clinical outcomes favorable or establish other-product safety.

[34] PIONEER-6 established cardiovascular noninferiority for oral semaglutide. The primary confidence interval did not establish superiority; no unregulated comparator.

[38] Cotadutide improved albuminuria in a phase 2 kidney-risk study. A surrogate and mixed receptor intervention do not establish clinical renal benefit or product equivalence.

[40] A phase 2 trial found substantial weight reduction with retatrutide. Triple receptor action and early-phase authentic product do not validate research-market retatrutide.

[41] Retatrutide improved metabolic and weight outcomes in a phase 2 diabetes study. Selected trial conditions and multiple receptor targets limit a pure GLP-1 mechanism claim.

[43] TRANSCEND-T2D-1 reported glycemic and weight benefits with retatrutide. The named trial formulation is not interchangeable with an unverified supplier vial.

[45] TRIUMPH-2 reported weight benefit with retatrutide in type 2 diabetes. Regulated trial-product findings do not test unregulated supply chains.

Tally: 31 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. The tally counts reports with discriminating intervention contrasts, including negative results; it is not a count of positive causal crossings. Shared parent trials and multiple manipulations within a study remain grouped.

Cap audit, precedence and Β/Γ/Δ boundary

Positive regulated-product clinical effects cross within that tested scope. The broad inference to unregulated supply binds a different claim and cannot inherit Ε. Α for SC3 is a universal narrative assessment, not a claim that an aging-specific cap literally defines manufacturing equivalence.

Universal six-cap audit: 1: In vitro evidence alone cannot exceed Γ; cell and biochemical findings do not establish human endogenous causality. 2: Pure association evidence cannot exceed Β; association-only presence/risk/reliability subclaims retain Β. 3: Overexpression in model systems caps at Γ for the broader claim; artificially engaged targets are not endogenous human necessity. 4: Biomarker change without functional/phenotypic change caps at Γ; clocks, concentrations and immune markers cannot replace functional outcomes. 5: Seeding or forced-transfer paradigms cap at Γ for endogenous propagation claims; injected spike, transferred IgG and forced model stimulation retain their model scope. 6: Familial/syndromic genetic findings remain scope-restricted; ALS/syndromic model mechanisms do not automatically establish general aging or sporadic human disease. None of these is reapplied to downgrade a genuinely convergent same-scope causal set.

Gamma hard-rule audit: Human associations and biomarker-only changes do not establish the broad causal claim. Model perturbations bind their tested species and phenotype, not an untested human scope. Positive treatment effects are checked for specific mechanism attribution; negative trials require target engagement before mechanistic falsification.

SC2 cap: “Pure association evidence — however large, however replicated — cannot exceed Β.” Small product assays and adverse-event observations establish measured mismatches, not reliable exposure across an unregulated market. The reliability proposition remains associational and is challenged, rather than causally established.

SC1 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. Randomized authentic products change weight and metabolic trajectories; selected trials also improve clinical kidney, cardiovascular and functional outcomes. Ε is restricted to trial products and tested populations, not arbitrary molecules bearing their names.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Small product assays and adverse-event observations establish measured mismatches, not reliable exposure across an unregulated market. The reliability proposition remains associational and is challenged, rather than causally established.

SC3 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. No selected controlled clinical comparison establishes research-chemical product efficacy equivalent to the trial formulations. Transferring a known molecule’s trial efficacy to unverified exposure is a narrative extrapolation.

Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC1 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: yes.

SC1 Ζ: “Requires: - Reproducible intervention effects - Mechanistic narrowing - Evidence not reducible to general sickness, caloric reduction, or developmental artifacts” Satisfied: no. To cross Ζ, establish mechanism-specific independent lines excluding shared pharmacological and product-exposure failures in the stated regulated scope.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Representative blinded batch assays and exposure studies must establish reliable identity, concentration, purity and sterility before outcomes, with denominators and repeat batches.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. A controlled clinical equivalence/noninferiority comparison of independently assayed preparations with exposure verification, prespecified margins and clinical endpoints.

Upper ladder: No convergence establishes the full registered claim. Positive narrower results are retained without re-capping an assembled causal set; their scopes and distinct failure modes are stated separately.

Independence: Different publications, laboratories and agents do not automatically form independent causal lines. No nominal Ζ or higher is assigned.

Falsification and pitfalls

Product and scope substitution. Using registrational trial efficacy as evidence for an unassayed vial.

Reporting denominator error. Treating spontaneous-report odds or selected poison calls as population incidence.

Analytical interpretation. Two body endotoxin values are upper bounds; an analytical purity measure is not the measured toxic fraction.

Adversarial steelman: above, then below

Case for Β: licensed products work and selected online samples contain the named peptide. This establishes biological plausibility and some identity observations but not even an adequate controlled outcome association for research-market equivalence.

Α is already the lowest defined rung. Counterfeit or impure products do not justify inventing a lower rung or concluding all unregulated products lack activity.

Retain Α for the exact equivalence proposition; preserve Ε for regulated-product causality and Β for measured supply observations.

Final score, causal direction and M/S/D

Overall Α applies to SC3, the preregistered clinical-equivalence proposition. It does not deny the efficacy of regulated GLP-1 medicines or prove that every research-market preparation is inactive. Product identity, exposure and clinical equivalence cannot be supplied by a chemical label or transferred from a registrational trial.

For the nominal research-market equivalence claim, no demonstrated clinical dependency connects this supply category to trial-equivalent outcomes. Step 2 is the framework’s operational classification under unresolved dependency, not proof that the active molecule or every preparation is causally inert. Regulated pharmacology is a different, causally supported subclaim.

Momentum: Mechanistic only. Recent online-product testing (PMID39509151), analytical comparison (PMID39379664) and adverse-event reports (PMID40285721) examine exposure/quality; no controlled research-market clinical-equivalence experiment was identified.

Stability: Stable. No specific pending result with a verified completion trigger was identified in this bounded search; Stable follows the framework definition, not a forecast of permanent truth.

Divergence: Contested. The split is between supplier and user-forum framing, which presents research-chemical preparations as delivering trial-grade results, and the regulatory, analytical and pharmacovigilance literature, which treats their identity and exposure as unverified; no single implied level and no single rung arithmetic applies. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Compare independently assayed candidate preparations against the authentic trial product under ethically authorized product-quality and clinical-trial oversight, with prespecified exposure and clinical equivalence margins; assay every batch before outcomes.

Readout: Verified exposure, prespecified functional/metabolic outcomes and adverse-event ascertainment. Controls: Authentic matched formulation, batch blinding, measured identity/potency/sterility, and identical follow-up. Supporting: Quality and exposure equivalence plus clinical results meeting the registered margins. Falsifying: Mismatched composition/exposure or failure of clinical equivalence despite verified adequate exposure.

KNOWLEDGE GAPS

Representative repeated-batch testing of research-market products.

Controlled clinical equivalence data for verified products.

Separation of formulation, administration and identity errors.

No market-wide incidence denominator for harm.

REVIEWER NOTES

Fifty to seventy original primary reports were selected before adjudication. Exact bounded abstract passages and selected body paragraphs are retained with examination receipts. Most papers were not read in full; absent details are limitations, not assumed controls. No independent blind grading, Scite or independent scientific peer review was performed, and no Consensus work informed the original grading; the dated Consensus consistency validation section above was added on 9 October 2026 as source reconciliation only and changed no grade or count. Popularity is editorial interest, not measured demand. Models are a descriptive tournament; their rankings are not independent causal proof. Grades were derived from selected primary evidence after claim registration, without consulting a previous completed grade. The primary-subclaim aggregation is fixed; weakest-link sensitivities remain displayed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14. Edition reviewed: the revised edition carrying the dated Consensus consistency validation section of 9 October 2026.

Scope of checks. All 51 REFERENCES PMIDs were verified against PubMed metadata for first author, title, journal and year; 51/51 resolve to the stated record, with no wrong identifier, retraction or expression of concern. The five additional identifiers appearing outside the numbered list were checked individually: PMID 38409593, 38913535 and 39413392 are Published Errata attached to parent trial rows; PMID 42137313 (Zinzi, EudraVigilance) and 42533250 (Kopp, impurities and potential immunogenicity) are the supplemental records the Consensus section introduces and explicitly excludes from the 51-source count. Because this review carries consumer-safety weight, every harm, dosing and contamination claim was checked against its source rather than sampled: Ashraf (39509151), where the locally verifiable Results give three delivered vials of six purchases, measured purity 7.7-14.37% against a 99% label claim, content 28.56-38.69% above label, and endotoxin in all three delivered vials with two of the three values reported as upper bounds (<2.8658 and <2.1645 EU/mg) and one measured at 8.9511 EU/mg — the review's insistence that the abstract's range not be repeated as three measured concentrations is correct, and it does not use that qualification to soften the finding that endotoxin was present in every delivered sample; Antonacci (41125326), a single case report of a 31-year-old admitted in hypoglycaemic coma after a website-sourced product whose toxicology identified insulin rather than semaglutide, reported here as one verified hazard and explicitly not as a frequency; Zinzi (42137313), 234 Individual Case Safety Reports for potential counterfeit semaglutide over 2018-2025 with 89.3% serious and disproportionality for hypoglycaemia and drug ineffectiveness, reported here as a signal without denominators or product authentication; Kopp (42533250), an in-vitro impurity and potential-immunogenicity study of follow-on and compounded products whose Novo Nordisk authorship the review discloses and which it correctly declines to treat as a grey-market sample or a patient outcome study; Hach (39379664), analytical testing of follow-on products that the review correctly declines to read as market-wide prevalence; and the regulated-product trial claims behind SC1 (STEP-1 33567185, SURMOUNT-1 35658024, SELECT 37952131, FLOW 38785209 and the retatrutide phase 2 and phase 3 reports 37366315, 37385280, 42250575, 42810372). No harm claim in this review is overstated beyond its source, and none is understated: the review states the hazards as demonstrated possibilities and separately states that no examined source supplies an exposed-user denominator. Scoring logic was re-derived: primary-subclaim aggregation on SC3 is applied as written, all three rules return Α, cap 2 is applied to SC2's reliability proposition, and Ε is preserved for regulated-product causality rather than being dragged down by the supply claim.

Findings

Rejected findings (checked, no change)

1. Α for SC3, and the headline. Checked in both directions, which matters most here. Α does not say grey-market products are inert or uniformly dangerous; the review says so explicitly, twice, and the AT A GLANCE line separates regulated efficacy from unverified equivalence. Nor is Α too generous: no examined source provides a controlled clinical comparison of independently assayed preparations, so the equivalence proposition has no evidence class above narrative. No change.
2. SC2 at Β rather than lower. Direct product assays are measurements, so the reliability proposition is associational-and-challenged rather than speculative. Cap 2 is correctly the binding rule.
3. Causal role "epiphenomenon" (derivation step 2). This sits awkwardly on a supply-chain claim rather than a biological mechanism. Retained: the derivation is written out, step 2 is the correct branch when no dependency is demonstrated in either direction, and the review states in terms that this is an operational classification and not a finding that the molecule or every preparation is inert.
4. Momentum "Mechanistic only" and Stability "Stable". Both carry the required artifact, name the specific records they rest on, and refuse the stronger label. The stability note explicitly frames itself as a bounded search finding rather than a forecast.
5. The endotoxin upper-bound qualification. Verified against the source's Results and retained. It narrows how two numbers may be quoted; it does not narrow the finding that endotoxin was detected in every delivered vial.
6. Treating poison-centre calls and spontaneous reports as signals rather than incidence. Correct, and listed as a named pitfall. The review does not convert the absence of a denominator into an absence of harm.
7. The supplemental status of PMID 42137313 and 42533250. Correctly excluded from the frozen 51-source count and labelled supplemental, so sources_total is not inflated by provider-discovered records.
8. Citation-year differences of one year from PubMed e-pub dates; PubMed titles dropping Greek letters. House convention. No collective-author rendering defect is present in this reference list. review_metadata.reviewer reads "Codex" here as it does corpus-wide; that is house provenance and was left alone.
9. The "Best-supported rival" field. Checked against the score card for the renderer defect that prints models_evaluated[0]: here that entry is the rank-1 non-nominal model (authentic-product pharmacology, is_nominal: false), while the nominal sits at rank 3. The prose is correct; no change.
10. Confidence band Moderate. Verified against the framework's confidence text rather than against access depth. High requires extensive independent replication across labs, models and assay modalities; the supply-side evidence is a handful of test purchases and voluntary reports, so Moderate is the highest defensible band even though the score card's confidence_rationale boilerplate also mentions incomplete access.

Residual limitations

One of 51 sources was examined beyond abstract depth, so apart from the online-purchase study the numeric claims rest on abstracts. Everything known about product quality in this market comes from a handful of test purchases and from voluntary reports with no exposed-user denominator; a reader should take neither the hazards nor their rarity as quantified. The review assesses equivalence of efficacy only — it is not a safety assessment of grey-market GLP-1 use, and nothing in it should be read as guidance on sourcing, dosing or self-administration.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Ashraf AR, Mackey TK, Vida RG et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of medical Internet research. 2024. PMID 39509151. DOI: 10.2196/65440. Access: full_text_partial. Study: PMID39509151.

2. McCall KL, Mastro Dwyer KA, Casey RT et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert opinion on drug safety. 2026. PMID 40285721. DOI: 10.1080/14740338.2025.2499670. Access: abstract_metadata. Study: PMID40285721.

3. Alabduljabbar K, Alsaqaaby M, Neff KJ et al. Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting. Endocrine. 2024. PMID 37735340. DOI: 10.1007/s12020-023-03534-0. Access: abstract_metadata. Study: PMID37735340.

4. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA internal medicine. 2024. PMID 38976257. DOI: 10.1001/jamainternmed.2024.2525. Access: abstract_metadata. Study: PMID38976257.

5. Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine. 2023. PMID 37952131. DOI: 10.1056/NEJMoa2307563. Access: abstract_metadata. Study: SELECT.

6. Aronne LJ, Horn DB, le Roux CW et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England journal of medicine. 2025. PMID 40353578. DOI: 10.1056/NEJMoa2416394. Access: abstract_metadata. Study: NCT05822830.

7. Wharton S, Lingvay I, Bogdanski P et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. The New England journal of medicine. 2025. PMID 40934115. DOI: 10.1056/NEJMoa2500969. Access: abstract_metadata. Study: NCT05564117.

8. Bliddal H, Bays H, Czernichow S et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England journal of medicine. 2024. PMID 39476339. DOI: 10.1056/NEJMoa2403664. Access: abstract_metadata. Study: NCT05064735.

9. Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2021. PMID 33567185. DOI: 10.1056/NEJMoa2032183. Access: abstract_metadata. Study: NCT03548935.

10. Weghuber D, Barrett T, Barrientos-Pérez M et al. Once-Weekly Semaglutide in Adolescents with Obesity. The New England journal of medicine. 2022. PMID 36322838. DOI: 10.1056/NEJMoa2208601. Access: abstract_metadata. Study: NCT04102189.

11. Garvey WT, Batterham RL, Bhatta M et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine. 2022. PMID 36216945. DOI: 10.1038/s41591-022-02026-4. Access: abstract_metadata. Study: NCT03693430.

12. Rubino D, Abrahamsson N, Davies M et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID 33755728. DOI: 10.1001/jama.2021.3224. Access: abstract_metadata. Study: NCT03548987.

13. Jastreboff AM, Aronne LJ, Ahmad NN et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine. 2022. PMID 35658024. DOI: 10.1056/NEJMoa2206038. Access: abstract_metadata. Study: SURMOUNT1.

14. Aronne LJ, Sattar N, Horn DB et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID 38078870. DOI: 10.1001/jama.2023.24945. Access: abstract_metadata. Study: NCT04660643.

15. Zhao L, Cheng Z, Lu Y et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024. PMID 38819983. DOI: 10.1001/jama.2024.9217. Access: abstract_metadata. Study: NCT05024032.

16. Malhotra A, Grunstein RR, Fietze I et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England journal of medicine. 2024. PMID 38912654. DOI: 10.1056/NEJMoa2404881. Access: abstract_metadata. Study: NCT05412004.

17. Jastreboff AM, le Roux CW, Stefanski A et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England journal of medicine. 2025. PMID 39536238. DOI: 10.1056/NEJMoa2410819. Access: abstract_metadata. Study: SURMOUNT1.

18. Packer M, Zile MR, Kramer CM et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine. 2025. PMID 39555826. DOI: 10.1056/NEJMoa2410027. Access: abstract_metadata. Study: SUMMIT.

19. Wadden TA, Chao AM, Machineni S et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature medicine. 2023. PMID 37840095. DOI: 10.1038/s41591-023-02597-w. Access: abstract_metadata. Study: NCT04657016.

20. Garvey WT, Frias JP, Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England). 2023. PMID 37385275. DOI: 10.1016/S0140-6736(23)01200-X. Access: abstract_metadata. Study: NCT04657003.

21. Coskun T, Sloop KW, Loghin C et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular metabolism. 2018. PMID 30473097. DOI: 10.1016/j.molmet.2018.09.009. Access: abstract_metadata. Study: NCT02759107.

22. Packer M, Zile MR, Kramer CM et al. Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial. Journal of the American College of Cardiology. 2025. PMID 40162940. DOI: 10.1016/j.jacc.2025.03.009. Access: abstract_metadata. Study: SUMMIT.

23. Mashayekhi M, Safa BI, Nian H et al. RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide. The Journal of endocrinology. 2025. PMID 41042549. DOI: 10.1530/JOE-25-0174. Access: abstract_metadata. Study: PMID41042549.

24. Lahooti A, Hoff AC, Critelli B et al. A Randomized, Double-Blind, Two-Way Cross-over Study to Evaluate the Efficacy of Liraglutide Treatment in Patients Undergoing Transoral Outlet Reduction Endoscopy for Weight Regain Post Roux-en-Y Gastric Bypass. Obesity surgery. 2025. PMID 39885064. DOI: 10.1007/s11695-025-07671-5. Access: abstract_metadata. Study: PMID39885064.

25. Lofton HF, Maranga G, Hold R et al. A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2025. PMID 39401933. DOI: 10.1016/j.soard.2024.08.037. Access: abstract_metadata. Study: PMID39401933.

26. Coppin G, Muñoz Tord D, Pool ER et al. A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity. International journal of obesity (2005). 2023. PMID 37626125. DOI: 10.1038/s41366-023-01370-w. Access: abstract_metadata. Study: PMID37626125.

27. Rubino DM, Greenway FL, Khalid U et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022. PMID 35015037. DOI: 10.1001/jama.2021.23619. Access: abstract_metadata. Study: NCT04074161.

28. Pi-Sunyer X, Astrup A, Fujioka K et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. The New England journal of medicine. 2015. PMID 26132939. DOI: 10.1056/NEJMoa1411892. Access: abstract_metadata. Study: NCT01272219.

29. Fox CK, Barrientos-Pérez M, Bomberg EM et al. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. The New England journal of medicine. 2025. PMID 39258838. DOI: 10.1056/NEJMoa2407379. Access: abstract_metadata. Study: NCT04775082.

30. Perkovic V, Tuttle KR, Rossing P et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England journal of medicine. 2024. PMID 38785209. DOI: 10.1056/NEJMoa2403347. Access: abstract_metadata. Study: FLOW.

31. McGuire DK, Marx N, Mulvagh SL et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. The New England journal of medicine. 2025. PMID 40162642. DOI: 10.1056/NEJMoa2501006. Access: abstract_metadata. Study: SOUL.

32. Marso SP, Bain SC, Consoli A et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine. 2016. PMID 27633186. DOI: 10.1056/NEJMoa1607141. Access: abstract_metadata. Study: NCT01720446.

33. Colhoun HM, Lingvay I, Brown PM et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature medicine. 2024. PMID 38796653. DOI: 10.1038/s41591-024-03015-5. Access: abstract_metadata. Study: SELECT.

34. Husain M, Birkenfeld AL, Donsmark M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine. 2019. PMID 31185157. DOI: 10.1056/NEJMoa1901118. Access: abstract_metadata. Study: NCT02692716.

35. Mann JFE, Rossing P, Bakris G et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nature medicine. 2024. PMID 38914124. DOI: 10.1038/s41591-024-03133-0. Access: abstract_metadata. Study: FLOW.

36. Marx N, Deanfield JE, Mann JFE et al. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 2025. PMID 40156843. DOI: 10.1161/CIRCULATIONAHA.125.074545. Access: abstract_metadata. Study: SOUL.

37. Pratley RE, Tuttle KR, Rossing P et al. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. Journal of the American College of Cardiology. 2024. PMID 39217553. DOI: 10.1016/j.jacc.2024.08.004. Access: abstract_metadata. Study: FLOW.

38. Selvarajah V, Robertson D, Hansen L et al. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney international. 2024. PMID 39218393. DOI: 10.1016/j.kint.2024.08.023. Access: abstract_metadata. Study: PMID39218393.

39. Mahaffey KW, Tuttle KR, Arici M et al. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. European heart journal. 2025. PMID 39211948. DOI: 10.1093/eurheartj/ehae613. Access: abstract_metadata. Study: FLOW.

40. Jastreboff AM, Kaplan LM, Frías JP et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine. 2023. PMID 37366315. DOI: 10.1056/NEJMoa2301972. Access: abstract_metadata. Study: RETATRUTIDE_PHASE2_OBESITY.

41. Rosenstock J, Frias J, Jastreboff AM et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England). 2023. PMID 37385280. DOI: 10.1016/S0140-6736(23)01053-X. Access: abstract_metadata. Study: RETATRUTIDE_PHASE2_T2D.

42. Sanyal AJ, Kaplan LM, Frias JP et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine. 2024. PMID 38858523. DOI: 10.1038/s41591-024-03018-2. Access: abstract_metadata. Study: RETATRUTIDE_PHASE2_OBESITY.

43. Bajaj HS, Welch M, Shah P et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England). 2026. PMID 42250575. DOI: 10.1016/S0140-6736(26)00967-0. Access: abstract_metadata. Study: NCT06354660.

44. Coskun T, Wu Q, Schloot NC et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology. 2025. PMID 40609566. DOI: 10.1016/S2213-8587(25)00092-0. Access: abstract_metadata. Study: RETATRUTIDE_PHASE2_T2D.

45. Bellido V, le Roux CW, Ekinci EI et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2026. PMID 42810372. DOI: 10.1016/S0140-6736(26)01861-1. Access: abstract_metadata. Study: NCT05929079.

46. Hach M, Engelund DK, Mysling S et al. Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. Pharmaceutical research. 2024. PMID 39379664. DOI: 10.1007/s11095-024-03771-6. Access: abstract_metadata. Study: PMID39379664.

47. Chun E, Siojo A, Rivera D et al. Weight loss and body composition after compounded semaglutide treatment in a real world setting. Diabetes, obesity & metabolism. 2025. PMID 39776038. DOI: 10.1111/dom.16162. Access: abstract_metadata. Study: PMID39776038.

48. Turnock LA, Hearne E, Germain J et al. Off-label GLP-1 weight-loss medicine use among online bodybuilders: Folk pharmacology, risk and harm reduction. The International journal on drug policy. 2025. PMID 40418873. DOI: 10.1016/j.drugpo.2025.104854. Access: abstract_metadata. Study: PMID40418873.

49. Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center-Case series. Journal of the American Pharmacists Association : JAPhA. 2023. PMID 37392810. DOI: 10.1016/j.japh.2023.06.017. Access: abstract_metadata. Study: PMID37392810.

50. Gaw CE, Hays HL, Kemp CA et al. Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2024. PMID 38421490. DOI: 10.1007/s13181-024-00999-x. Access: abstract_metadata. Study: PMID38421490.

51. Antonacci G, Bortignon E, Bolognesi M et al. Hypoglycaemic coma induced by a falsified semaglutide product: a case report. European journal of hospital pharmacy : science and practice. 2026. PMID 41125326. DOI: 10.1136/ejhpharm-2025-004656. Access: abstract_metadata. Study: PMID41125326.

Source-specific evidence cards

[1] Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study.

Shows: Purchased online semaglutide samples contained the named peptide but had analytical and label mismatches.

Does not show: Three delivered samples cannot estimate market-wide reliability; purity measurements do not identify the toxicity of every impurity. Two endotoxin results in the body are upper bounds, not quantified concentrations.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Results:paragraph15, 2:Results:paragraph27, 2:Results:paragraph28, 2:Results:paragraph32. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[2] Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.

Shows: Compounded GLP-1 adverse-event reports disproportionately included quality and administration problems.

Does not show: Spontaneous reporting odds are not incidence; compounded and research-market products are different categories.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[3] Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting.

Shows: Prescribed semaglutide was associated with weight loss in clinical practice.

Does not show: An observational prescription cohort does not test unregulated products or eliminate attrition bias.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[4] Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.

Shows: A matched prescription cohort associated tirzepatide with greater weight loss than semaglutide.

Does not show: Residual confounding and treatment discontinuation remain; neither product was an unregulated comparator.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[5] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

Shows: SELECT randomized semaglutide reduced cardiovascular events in obesity with prior cardiovascular disease.

Does not show: This is regulated-product efficacy in a selected high-risk population, not identity or bioequivalence of online vials.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[6] Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

Shows: SURMOUNT-5 randomized comparison favored tirzepatide over semaglutide for weight loss.

Does not show: Open-label comparison and dual receptor pharmacology do not establish equivalence of research-sourced molecules.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[7] Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.

Shows: OASIS-4 found weight reduction with the tested oral semaglutide formulation.

Does not show: Formulation-specific trial results cannot establish absorption or efficacy of a different product.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[8] Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.

Shows: STEP-9 improved weight, knee pain and function with semaglutide in obesity and knee osteoarthritis.

Does not show: Weight mediation and the selected clinical context remain; unregulated sourcing was not tested.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[9] Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Shows: STEP-1 demonstrated weight loss with randomized regulated semaglutide.

Does not show: Authentic trial-product exposure is the controlled variable; a supplier's chemical name alone is not that exposure.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[10] Once-Weekly Semaglutide in Adolescents with Obesity.

Shows: STEP-TEENS reduced BMI with semaglutide in adolescents.

Does not show: Developmental context and BMI endpoints differ from adult outcomes; no online-product comparison.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[11] Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.

Shows: STEP-5 showed sustained weight loss over two years with semaglutide.

Does not show: Sustained trial efficacy does not establish batch consistency elsewhere.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[12] Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Shows: STEP-4 continuation maintained weight loss whereas withdrawal led to regain.

Does not show: The randomized population completed a tolerability run-in; withdrawal of an authentic product is not a supply-chain test.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[13] Tirzepatide Once Weekly for the Treatment of Obesity.

Shows: SURMOUNT-1 demonstrated weight reduction with tirzepatide.

Does not show: Dual GIP/GLP-1 action and regulated manufacture cannot be assigned to an unassayed vial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[14] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.

Shows: SURMOUNT-4 continuation and withdrawal separated weight trajectories.

Does not show: Run-in selection restricts generality; the trial does not establish unregulated equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[15] Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.

Shows: SURMOUNT-CN found weight reduction with tirzepatide in a Chinese population.

Does not show: The attached erratum was identified but not fully audited; product equivalence remains untested.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID 38913535. Subclaims: SC1.

[16] Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.

Shows: SURMOUNT-OSA reduced apnea severity and weight with tirzepatide.

Does not show: Weight-related mediation and the attached erratum limit a broad mechanism inference; no grey-market arm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID 39413392. Subclaims: SC1.

[17] Tirzepatide for Obesity Treatment and Diabetes Prevention.

Shows: Longer SURMOUNT-1 follow-up supported diabetes prevention in obesity with prediabetes.

Does not show: This is a later report of the same trial family, not an independent manufacturing or mechanism test.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[18] Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

Shows: SUMMIT improved the cardiovascular-death/worsening-heart-failure composite and function in obesity with HFpEF.

Does not show: Composite benefit does not prove a mortality-alone effect or unregulated equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[19] Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.

Shows: SURMOUNT-3 improved weight after an intensive lifestyle lead-in.

Does not show: Lead-in eligibility and an attached erratum restrict interpretation; authentic formulation was tested.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Erratum in: PMID 38409593. Subclaims: SC1.

[20] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Shows: SURMOUNT-2 improved weight in obesity with type 2 diabetes.

Does not show: Diabetic context differs from other populations; sourcing equivalence was not randomized.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[21] LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.

Shows: LY3298176 preclinical and early clinical studies supported dual receptor effects on metabolic outcomes.

Does not show: Early phase and mixed receptor action do not prove long-term outcomes or online-product identity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[22] Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.

Shows: SUMMIT kidney subgroup analyses reported benefit with differing creatinine and cystatin estimates.

Does not show: Same trial family; body composition can affect filtration estimates, and subgroup findings do not establish product equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[23] RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide.

Shows: A GLP-1 receptor variant was associated with differing liraglutide responses.

Does not show: Genotype association is not randomized receptor perturbation or a product comparison.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[24] A Randomized, Double-Blind, Two-Way Cross-over Study to Evaluate the Efficacy of Liraglutide Treatment in Patients Undergoing Transoral Outlet Reduction Endoscopy for Weight Regain Post Roux-en-Y Gastric Bypass.

Shows: Liraglutide after an endoscopic bariatric procedure improved weight outcomes under tested timing conditions.

Does not show: Procedure and timing restrict generalization; no grey-market sourcing comparison.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[25] A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.

Shows: Liraglutide supported weight loss after gastric bypass.

Does not show: Pandemic-related attrition and a postsurgical population limit generality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[26] A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity.

Shows: Liraglutide-induced weight loss occurred without measured changes in food liking in the tested study.

Does not show: A null selected mediator measure does not rule out all appetite mechanisms or test unregulated products.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[27] Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Shows: STEP-8 favored semaglutide over liraglutide for weight loss.

Does not show: Comparative authentic formulations do not establish equivalence across suppliers.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[28] A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Shows: SCALE supported liraglutide-induced weight loss.

Does not show: This supports licensed intervention efficacy, not research-market efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[29] Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.

Shows: Liraglutide reduced BMI in children under the study conditions.

Does not show: Childhood growth and BMI outcomes cannot be read as universal adult weight loss.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[30] Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

Shows: FLOW reduced a clinical kidney/cardiovascular composite in type 2 diabetes with CKD.

Does not show: Disease scope is constrained; no unregulated preparation was assessed.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[31] Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.

Shows: SOUL reduced major cardiovascular events with oral semaglutide.

Does not show: Confirmatory secondary endpoints were not all positive; trial formulation is material to the result.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[32] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Shows: SUSTAIN-6 supported cardiovascular noninferiority and reported more retinopathy complications.

Does not show: A benefit signal does not make all clinical outcomes favorable or establish other-product safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[33] Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.

Shows: SELECT kidney analyses reported a secondary kidney benefit.

Does not show: Same SELECT family; not independent evidence of product identity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[34] Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Shows: PIONEER-6 established cardiovascular noninferiority for oral semaglutide.

Does not show: The primary confidence interval did not establish superiority; no unregulated comparator.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[35] Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.

Shows: FLOW subgroup analyses assessed outcomes with and without baseline SGLT2 inhibitor use.

Does not show: Wide subgroup uncertainty and shared parent trial preclude a new independent causal line.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[36] Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.

Shows: SOUL analyses found broadly consistent cardiovascular results across SGLT2 inhibitor strata.

Does not show: Same trial family and nonsignificant interaction do not prove identical effects in every stratum.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[37] Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.

Shows: FLOW secondary analyses supported heart-failure outcomes.

Does not show: Shared participants and intervention mean this is not a separate independent line.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[38] A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.

Shows: Cotadutide improved albuminuria in a phase 2 kidney-risk study.

Does not show: A surrogate and mixed receptor intervention do not establish clinical renal benefit or product equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[39] Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.

Shows: FLOW analyses supported cardiovascular consistency across CKD severity.

Does not show: Same parent trial; subgroup consistency is not universal equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[40] Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

Shows: A phase 2 trial found substantial weight reduction with retatrutide.

Does not show: Triple receptor action and early-phase authentic product do not validate research-market retatrutide.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[41] Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.

Shows: Retatrutide improved metabolic and weight outcomes in a phase 2 diabetes study.

Does not show: Selected trial conditions and multiple receptor targets limit a pure GLP-1 mechanism claim.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[42] Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Shows: Retatrutide reduced liver fat in an obesity-trial substudy.

Does not show: Surrogate endpoint and shared cohort do not establish liver clinical outcomes or independent replication.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[43] Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.

Shows: TRANSCEND-T2D-1 reported glycemic and weight benefits with retatrutide.

Does not show: The named trial formulation is not interchangeable with an unverified supplier vial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[44] Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.

Shows: A retatrutide diabetes-trial substudy measured fat and lean-mass changes.

Does not show: Shared cohort and body-composition endpoints do not prove net healthspan benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[45] Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Shows: TRIUMPH-2 reported weight benefit with retatrutide in type 2 diabetes.

Does not show: Regulated trial-product findings do not test unregulated supply chains.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[46] Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs.

Shows: Analytical comparison of follow-on GLP-1 products found formulation and impurity differences.

Does not show: Clinical consequences were not directly measured; tested follow-on products are not a market-wide random sample.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[47] Weight loss and body composition after compounded semaglutide treatment in a real world setting.

Shows: A compounded semaglutide/cyanocobalamin cohort reported weight and body-composition changes.

Does not show: Uncontrolled combination treatment is neither research-market testing nor a randomized equivalence trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[48] Off-label GLP-1 weight-loss medicine use among online bodybuilders: Folk pharmacology, risk and harm reduction.

Shows: Qualitative interviews described online drug-use practices and perceived effects among bodybuilders.

Does not show: Self-selection, co-use and unverified identity prevent causal efficacy or incidence estimates.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[49] Administration errors of compounded semaglutide reported to a poison control center-Case series.

Shows: Poison-center cases documented adverse events after compounded semaglutide administration errors.

Does not show: Selected cases cannot measure population risk or separate every formulation problem from administration error.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[50] Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022.

Shows: Poison-center surveillance recorded GLP-1 exposures, many involving therapeutic errors.

Does not show: All GLP-1 exposures are not grey-market exposures, and reported calls are not incidence denominators.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[51] Hypoglycaemic coma induced by a falsified semaglutide product: a case report.

Shows: A falsified Ozempic case identified insulin in a product associated with coma.

Does not show: One counterfeit case establishes a possibility, not the prevalence or efficacy of all research-market products.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-addendum.md
• consensus-validation.json
• edition-approval-audit.json
• grey-market-glp1.review.md
• grey-market-glp1.scorecard.json
• reader-summary.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt

Sources: 51 · load-bearing claims: 55 · verified: 55 · unverified: 0 · contradicted: 0 · schema 5.3